艾伯维(ABBV.US)与仿制药企业就核心免疫药物Rinvoq达成和解

Core Viewpoint - AbbVie has reached a settlement with all involved generic drug companies regarding the lawsuits related to the planned launch of a generic version of Rinvoq, a key immunotherapy product in AbbVie's portfolio [1] Group 1: Legal Developments - AbbVie announced a settlement that resolves litigation against generic drug companies seeking to launch a non-patented version of Rinvoq [1] - The settlement and licensing agreement will prevent generic versions of Rinvoq tablets from entering the U.S. market until April 2037 [1] Group 2: Product Positioning - AbbVie positions Rinvoq and its sister drug Skyrizi as potential replacements for Humira, which lost its U.S. market exclusivity in 2023 [1] - Rinvoq's net sales reached $2.7 billion in the first half of 2025, reflecting a year-over-year growth of approximately 53% [1] Group 3: Market Comparison - In contrast, Humira's sales in the U.S. market declined by about 63% during the same period [1]